Vanguard Group Inc. Has $3 Billion Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Vanguard Group Inc. raised its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 0.8% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 12,733,399 shares of the biopharmaceutical company’s stock after buying an additional 98,303 shares during the quarter. Vanguard Group Inc. owned 9.87% of Alnylam Pharmaceuticals worth $2,996,296,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in ALNY. Mutual of America Capital Management LLC grew its holdings in Alnylam Pharmaceuticals by 26.7% during the third quarter. Mutual of America Capital Management LLC now owns 1,924 shares of the biopharmaceutical company’s stock valued at $529,000 after purchasing an additional 405 shares during the period. Pathstone Holdings LLC grew its holdings in shares of Alnylam Pharmaceuticals by 11.2% in the 3rd quarter. Pathstone Holdings LLC now owns 6,249 shares of the biopharmaceutical company’s stock valued at $1,719,000 after buying an additional 629 shares during the period. Advisors Asset Management Inc. increased its position in shares of Alnylam Pharmaceuticals by 4.1% in the 3rd quarter. Advisors Asset Management Inc. now owns 4,767 shares of the biopharmaceutical company’s stock valued at $1,311,000 after buying an additional 189 shares in the last quarter. Cerity Partners LLC raised its stake in Alnylam Pharmaceuticals by 133.6% during the 3rd quarter. Cerity Partners LLC now owns 13,019 shares of the biopharmaceutical company’s stock worth $3,581,000 after buying an additional 7,445 shares during the period. Finally, Algert Global LLC lifted its holdings in Alnylam Pharmaceuticals by 401.3% during the third quarter. Algert Global LLC now owns 9,825 shares of the biopharmaceutical company’s stock worth $2,702,000 after acquiring an additional 7,865 shares in the last quarter. Institutional investors own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Stock Down 3.4 %

ALNY stock opened at $280.96 on Wednesday. Alnylam Pharmaceuticals, Inc. has a 1-year low of $141.98 and a 1-year high of $304.39. The business’s 50 day simple moving average is $258.62 and its 200 day simple moving average is $260.26. The company has a current ratio of 2.78, a quick ratio of 2.71 and a debt-to-equity ratio of 15.27. The firm has a market capitalization of $36.37 billion, a PE ratio of -129.47 and a beta of 0.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) EPS for the quarter, missing the consensus estimate of ($0.62) by ($0.03). As a group, research analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

Insider Buying and Selling at Alnylam Pharmaceuticals

In related news, CMO Pushkal Garg sold 52,592 shares of the business’s stock in a transaction that occurred on Monday, January 27th. The stock was sold at an average price of $285.00, for a total value of $14,988,720.00. Following the completion of the sale, the chief marketing officer now directly owns 11,989 shares in the company, valued at approximately $3,416,865. The trade was a 81.44 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Yvonne Greenstreet sold 1,213 shares of the firm’s stock in a transaction on Friday, February 14th. The stock was sold at an average price of $255.17, for a total value of $309,521.21. Following the transaction, the chief executive officer now owns 81,526 shares in the company, valued at approximately $20,802,989.42. This trade represents a 1.47 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 71,234 shares of company stock valued at $19,958,097 in the last ninety days. 1.50% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

ALNY has been the subject of several recent analyst reports. HC Wainwright increased their price target on Alnylam Pharmaceuticals from $400.00 to $500.00 and gave the stock a “buy” rating in a report on Monday, February 24th. Royal Bank of Canada raised their target price on shares of Alnylam Pharmaceuticals from $310.00 to $330.00 and gave the stock an “outperform” rating in a report on Friday, March 21st. William Blair reiterated an “outperform” rating on shares of Alnylam Pharmaceuticals in a report on Friday, March 21st. Needham & Company LLC restated a “buy” rating and set a $320.00 price objective on shares of Alnylam Pharmaceuticals in a report on Friday, March 21st. Finally, Scotiabank upped their target price on shares of Alnylam Pharmaceuticals from $300.00 to $338.00 and gave the stock a “sector outperform” rating in a research note on Friday, March 21st. One analyst has rated the stock with a sell rating, five have assigned a hold rating and twenty have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $312.30.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.